Novo Holdings A/S — SEC Form 4 filings
SEC reporting owner CIK 1388325. 10 Form 4 filings on record with FilingPulse; latest filed 2026-05-06.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-13 to 2026-05-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 2,408,496 shares, $39,224,987 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 6 filings — 5,564,954 shares, $5,298,689 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 952,941 shares @ $17.00 ($16,199,997) in MapLight Therapeutics, Inc., filed 2025-10-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | 10% owner | 1 | 1 leg · 952,941 sh · $16,199,997 | — | 3 |
| Metagenomi, Inc. (MGX) | 10% owner | 1 | 2 legs · 900,000 sh · $13,025,000 | — | 3 |
| Avalyn Pharma Inc. (AVLN) | 10% owner | 1 | 1 leg · 555,555 sh · $9,999,990 | — | 6 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | 10% owner | 3 | — | 5 legs · 4,172,336 sh · $3,408,657 | — |
| IO Biotech, Inc. (IOBT) | 10% owner | 3 | — | 4 legs · 1,392,618 sh · $1,890,032 | — |
| Hemab Therapeutics Holdings, Inc. (COAG) | 10% owner | 1 | — | — | 5 |
Form 4 filings — Novo Holdings A/S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-06 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) | Conversion (C): 4,180,550 · Conversion (C): 23,343 (derivative) @ $0 · Conversion (C): 71,866 (derivative) @ $0 · Conversion (C): 62,121 (derivative) @ $0 · Conversion (C): 32,695 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Avalyn Pharma Inc. (AVLN) | Conversion (C): 3,327,734 · Purchase (P): 555,555 @ $18 · Conversion (C): 18,000,000 (derivative) @ $0 · Conversion (C): 1,986,369 (derivative) @ $0 · Conversion (C): 25,899,284 (derivative) @ $0 · Conversion (C): 5,587,603 (derivative) @ $0 · +1 more | EDGAR |
| 2025-10-30 | 4 | MapLight Therapeutics, Inc. (MPLT) | Conversion (C): 2,733,681 · Purchase (P): 952,941 @ $17 · Conversion (C): 26,191,207 (derivative) @ $0 · Conversion (C): 19,734,671 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | IO Biotech, Inc. (IOBT) | Sale (S): 51,522 @ $1.33 · Sale (S): 23,478 @ $1.31 | EDGAR |
| 2024-05-14 | 4 | IO Biotech, Inc. (IOBT) | Sale (S): 658,809 @ $1.22 | EDGAR |
| 2024-03-25 | 4 | SPRUCE BIOSCIENCES, INC. (SPRB) | Sale (S): 465,021 @ $0.75 | EDGAR |
| 2024-03-20 | 4 | SPRUCE BIOSCIENCES, INC. (SPRB) | Sale (S): 842,020 @ $0.77 · Sale (S): 593,000 @ $0.76 · Sale (S): 359,979 @ $0.73 | EDGAR |
| 2024-03-18 | 4 | SPRUCE BIOSCIENCES, INC. (SPRB) | Sale (S): 1,912,316 @ $0.89 | EDGAR |
| 2024-02-15 | 4 | Metagenomi, Inc. (MGX) | Purchase (P): 100,000 @ $10.25 · Conversion (C): 839,175 · Purchase (P): 800,000 @ $15 · Conversion (C): 147,415 (derivative) · Conversion (C): 691,760 (derivative) | EDGAR |
| 2024-02-13 | 4 | IO Biotech, Inc. (IOBT) | Sale (S): 658,809 @ $1.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1388325 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →